Clene (NASDAQ:CLNN – Free Report) had its price target hoisted by HC Wainwright from $7.00 to $31.00 in a research note released on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Clene’s Q3 2024 earnings at ($1.32) EPS, Q4 2024 earnings at ($1.55) EPS, FY2024 earnings at ($5.62) EPS, FY2025 earnings at ($5.80) EPS, FY2026 earnings at ($4.82) EPS, FY2027 earnings at $1.41 EPS and FY2028 earnings at $12.59 EPS.
Several other research firms have also recently weighed in on CLNN. Canaccord Genuity Group reiterated a buy rating and issued a $94.00 target price on shares of Clene in a research note on Tuesday, August 6th. Benchmark reiterated a buy rating and issued a $100.00 target price on shares of Clene in a research note on Thursday, May 23rd. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Clene presently has a consensus rating of Buy and a consensus target price of $101.00.
Get Our Latest Research Report on Clene
Clene Stock Performance
Clene (NASDAQ:CLNN – Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.60) by $0.54. Clene had a negative net margin of 7,873.23% and a negative return on equity of 224.28%. The business had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.10 million. As a group, analysts predict that Clene will post -6.8 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Clene stock. Csenge Advisory Group boosted its holdings in shares of Clene Inc. (NASDAQ:CLNN – Free Report) by 131.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 269,600 shares of the company’s stock after purchasing an additional 153,000 shares during the period. Csenge Advisory Group owned about 0.21% of Clene worth $96,000 as of its most recent SEC filing. 23.28% of the stock is owned by institutional investors.
About Clene
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Read More
- Five stocks we like better than Clene
- Stock Sentiment Analysis: How it Works
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.